Please use this identifier to cite or link to this item:
Title: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Authors: Hymowitz, Sarah G.
Jin, Sha
Khaw, Seong Lin
Kovar, Peter J.
Lam, Lloyd T.
Lee, Jackie
Maecker, Heather L.
Marsh, Kennan C.
Mason, Kylie D.
Mitten, Michael J.
Sampath, Deepak
Nimmer, Paul M.
Oleksijew, Anatol
Park, Chang H.
Park, Cheol-Min
Phillips, Darren C.
Roberts, Andrew W.
Seymour, John F.
Smith, Morey L.
Sullivan, Gerard M.
Tahir, Stephen K.
Wendt, Michael D.
Xiao, Yu
Xue, John C.
Zhang, Haichao
Humerickhouse, Rod A.
Rosenberg, Saul H.
Elmore, Steven W.
Tse, Chris
Souers, Andrew J.
Leverson, Joel D.
Boghaert, Erwin R.
Ackler, Scott L.
Catron, Nathaniel D.
Chen, Jun
Dayton, Brian D.
Ding, Hong
Enschede, Sari H.
Fairbrother, Wayne J.
Huang, David C. S.
Keywords: DRNTU::Science::Chemistry::Biochemistry
Issue Date: 2013
Source: Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature medicine, 19(2), 202-208.
Series/Report no.: Nature medicine
Abstract: Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2–like 1 (BCL-XL), which has shown clinical efficacy in some BCL-2–dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-XL inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2–dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2–dependent hematological cancers.
DOI: 10.1038/nm.3048
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SPMS Journal Articles

Citations 1

Updated on Dec 28, 2021

Citations 1

Updated on Mar 6, 2021

Page view(s) 10

Updated on Jan 17, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.